Biotech & Pharma

Pharma Races to Scale AI as Billions Flow into Drug Discovery

23 sec read23 views0 listens

Billion-dollar investments are pouring into end-to-end AI platforms for drug discovery, enabling more powerful biological models through integrated datasets and reasoning workflows. This trend is driven by the potential to accelerate biomedical research and expand druggable targets beyond traditional limits, as seen in Isomorphic Labs' partnerships with major pharma companies.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & Pharma5 days ago29 sec read

Human Cell Atlas at 10: A Decade of Discovery and the Road to HCA 2.0

The Human Cell Atlas (HCA) celebrated its 10-year anniversary, marking significant advancements in single-cell and spatial data generation for tissue and organ systems. The project is now transitioning to HCA 2.0, focusing on scaling spatial atlases,...

Ali Nemati

Health & MedicineAug 330 sec read

Episode 1153: Don't Use Vitamin C For This Either...

A recent randomized trial found that administering high-dose intravenous Vitamin C (10g) to comatose adults after out-of-hospital cardiac arrest did not improve organ function and, in fact, worsened outcomes. The study indicated worse organ function,...

Ali Nemati

GamingJul 2327 sec read

Matt Damon Almost Starred as Robin in Two Different Batman Movies

A study comparing rivaroxaban followed by aspirin versus aspirin alone for thromboprophylaxis after total knee or hip arthroplasty found no significant difference in preventing venous thromboembolism or in bleeding events. This suggests aspirin alone...

Ali Nemati